Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron's share price has climbed by more than 100% over five years and is trading near its record high. The company sells a variety of products across indications and has a solid pipeline that could drive future growth.

Stock Split Watch: Is Regeneron Pharmaceuticals Next?

If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two most common subtypes of non-Hodgkin lymphoma

Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review

TARRYTOWN, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2023 financial and operating results on Thursday, November 2, 2023, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023

If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 inflammation that impacts the ability to eat

Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review

TARRYTOWN, N.Y., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company's gene therapy and auditory programs.

Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss

Biogen

bluebird bio

BioMarin Pharmaceutical

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Novartis

Solid Biosciences

Sarepta Therapeutics

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASDAQ: SRPT, which are developing gene therapies. ‘

Are Gene Therapy Stocks The Market's Next Big Winners?

Regeneron's sales growth rate has been struggling over the past year. Revenue from its top-selling drug, Eylea, fell 7% in the most recent quarter.

This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost

Regeneron Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Tarrytown that has played a key role in the fight against COVID-19. Regeneron's revenue for the second quarter of 2023 was $3.16 billion, an increase of 10.5% compared to the second quarter of 2022. At the end of the second quarter, the remaining authorization to repurchase Regeneron Pharmaceuticals shares amounted to $2.332 billion.

Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare

Regeneron Pharmaceuticals Inc.'s REGN, +0.74% agreement with the federal government to limit the list price of any new COVID monoclonal antibody commercialized as a result of their public-private partnership may have “far-reaching consequences” for drug pricing, Beacon Policy Advisors analysts wrote in a note Friday. Under the deal, part of the federal government's Project NextGen initiative to accelerate development of new COVID vaccines and treatments, Regeneron agreed that the U.S. list price of any new product stemming from the partnership will be less than or equal to its price in comparable markets globally, the U.S. Department of Health and Human Services announced last week.

Regeneron's pricing deal with federal government may have ‘far-reaching consequences,' analysts say

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Morgan Stanley 21st Annual Global Healthcare Conference September 11, 2023 9:20 AM ET Company Participants Ryan Crowe - VP, IR Marion McCourt - EVP, Commercial Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. Thanks for joining us.

Regeneron Pharmaceuticals, Inc. (REGN) Management presents at Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)

Regeneron stock (NASDAQ: REGN) has seen a 6% rise in a month, compared to a 1% fall for the broader S&P500 index.

Is Regeneron Stock Fully Valued At $820?

Eli Lilly

Vertex Pharmaceuticals

Eli Lilly is a healthcare giant poised to get even bigger. Regeneron Pharmaceuticals has nowhere to go but up.

3 Unstoppable Growth Stocks to Buy Right Now

Regeneron Pharmaceuticals Inc. REGN, +0.66% said late Friday that Chief Financial Officer Robert E. Landry will retire in February, and Christopher Fenimore, the pharma company's current head of accounting and controller, will succeed Landry upon his retirement.

Regeneron CFO Landry to retire, top accountant Fenimore to become CFO

Robert E. Landry to retire effective February 2024; Christopher Fenimore, long-standing Senior Vice President, Head of Accounting and Controller, to assume CFO role Robert E. Landry to retire effective February 2024; Christopher Fenimore, long-standing Senior Vice President, Head of Accounting and Controller, to assume CFO role

Regeneron Provides Update on Planned Chief Financial Officer Transition

Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., join Regeneron's Board of Directors Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., join Regeneron's Board of Directors

Regeneron Announces Updates to Board of Directors

Vertex and Regeneron have delivered solid financial results and stock market performance. Both biotechs have exciting pipelines that should produce key new approvals or label expansions.

2 Top Biotech Stocks to Buy in September

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 2023 Wells Fargo Healthcare Conference Transcript September 6, 2023 8:45 AM ET Executives Marion McCourt - Head, Commercial Ryan Crowe - Head, Investor Relations Analysts Mohit Bansal - Wells Fargo Mohit Bansal Good morning. My name is Mohit Bansal.

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at 2023 Wells Fargo Healthcare Conference (Transcript)

SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc. today announced a clinical trial supply agreement with Regeneron for the use of Libtayo® (cemiplimab) in ONM-501 study.

OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo® (cemiplimab) in ONM-501 Study

Decibel Therapeautics

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Decibel Therapeutics, Inc. (NasdaqGS: DBTX) to Regeneron Pharmaceuticals, Inc. (NasdaqGS: REGN). Under the terms of the proposed transaction, shareholders of Decibel will receive only $4.00 in cash for each share of Decibel that they own, with an additional non-tradeable contingent value right (CVR) to receive.

DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTX

Regeneron (REGN) gains 13% in a month on the FDA's approval of a higher dose of Eylea and other positive updates.

Regeneron (REGN) Gains 13% in 1 Month on FDA Nod For Eylea HD

AstraZeneca

Merck

The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.

Oncology Market's Huge Potential Puts These Stocks in Focus

Regeneron's latest regulatory approval comes at an opportune time. The company's current lineup should continue generating growing sales.

Is Regeneron Stock a Buy Now?

Regeneron Pharmaceuticals Inc. REGN, -0.32% said Tuesday that the Biomedical Advanced Research and Development Authority has agreed to support the development, manufacturing and licensure of a next-generation COVID-19 monoclonal antibody. The agreement, part of the U.S. Department of Health and Human Services' Project NextGen initiative, provides up to $326 million of government funding, Regeneron said, noting that the federal agency will fund up to 70% of Regeneron's costs for certain clinical development activities for the therapy.

Regeneron gets federal funding for next-generation COVID treatment

Program is part of U.S. Government's ‘Project NextGen' and provides partial funding for clinical development of a novel monoclonal antibody therapy Program is part of U.S. Government's ‘Project NextGen' and provides partial funding for clinical development of a novel monoclonal antibody therapy

Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention

Amgen

Arista Networks

APA Corporation

Constellation Energy Corp

Global Payments

Jacobs Solutions Inc

The S&P 500's plunge in August caught most investors off guard. It's quite a win if you scooped up the handful of gainers in the tough month.

News for Regeneron Pharmaceuticals Stock (REGN)